ArticleRheumatology (Oxford, England)2023
Association between psoriatic disease and lifestyle factors and comorbidities: cross-sectional analysis and Mendelian randomization.
Article in Rheumatology (Oxford, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Does Prior Exposure Affect Retention? A Real-World, Multicentre Assessment of IL-17 Inhibitor Cycling in Psoriatic Arthritis.Rheumatology and therapy · 2026Article
- MPGK: A user-friendly tool for Mendelian randomization, polygenic risk score, Geno Ontology, and the Kyoto Encyclopedia of Genes and Genomes analysis.Chinese medical journal · 2026Article
- The impact of smoking and obesity on secukinumab effectiveness in psoriatic arthritis: real-world evidence from 1202 European patients.EULAR rheumatology open · 2026Article
- Psoriasis as a systemic inflammatory disease: an immune set-point framework for comorbidities and relapse.Frontiers in immunology · 2026Review
- Disentangling Nicotine vs Non-Nicotine Components of Tobacco Exposure in Psoriasis and Psoriatic Arthritis: A Multivariable and Trans-Ethnic Mendelian Randomization Study.Clinical, cosmetic and investigational dermatology · 2026Article
- Dietary habits, nutritional supplement use, and adherence to national dietary guidelines in patients with psoriasis.Scientific reports · 2025Article
- Safety assessment of apremilast: real-world adverse event analysis from the FAERS database.Archives of dermatological research · 2025Article
- The comparative prevalence of comorbidities across rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis.Rheumatology advances in practice · 2025Article
- Therapeutic strategy in psoriatic arthritis: choosing the right treatment for the right patient.Therapeutic advances in musculoskeletal disease · 2025Article
- Exploring the Link Between Genetic Predictors of Cardiovascular Disease and Psoriasis.JAMA cardiology · 2024Article
- Alcohol consumption and risk of psoriasis: Results from observational and genetic analyses in more than 100,000 individuals from the Danish general population.JAAD international · 2024Article
- Neighborhood characteristics and the risk of psoriasis: A systematic review.JAAD international · 2023Article
- Review
- Genetic causal relationship between gut microbiome and psoriatic arthritis: a bidirectional two-sample Mendelian randomization study.Frontiers in microbiology · 2023Article
- Smoking is an independent but not a causal risk factor for moderate to severe psoriasis: A Mendelian randomization study of 105,912 individuals.Frontiers in immunology · 2023Article
- Non-alcoholic fatty liver disease is not a causal risk factor for psoriasis: A Mendelian randomization study of 108,835 individuals.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
objectivesTo examine associations between PsA and psoriasis vs lifestyle factors and comorbidities by triangulating observational and genetic evidence.
methodsWe analysed cross-sectional data from the UK Biobank (1836 PsA, 8995 psoriasis, 36 000 controls) to describe the association between psoriatic disease and lifestyle factors (including BMI and smoking) and 15 comorbidities [including diabetes and coronary artery disease (CAD)] using logistic models adjusted for age, sex and lifestyle factors. We applied bidirectional Mendelian randomization (MR) to genome-wide association data (3609 PsA and 7804 psoriasis cases, up to 1.2 million individuals for lifestyle factors and 757 601 for comorbidities) to examine causal direction, using the inverse-variance weighted method.
resultsBMI was cross-sectionally associated with risk of PsA (OR 1.31 per 5 kg/m2 increase; 95% CI 1.26, 1.37) and psoriasis (OR 1.23; 1.20, 1.26), with consistent MR estimates (PsA OR 1.38; 1.14, 1.67; psoriasis OR 1.36; 1.18, 1.58). In both designs, smoking was more strongly associated with psoriasis than PsA. PsA and psoriasis were cross-sectionally associated with diabetes (OR 1.35 and 1.39, respectively) and CAD (OR 1.56 and 1.38, respective). Genetically predicted glycated haemoglobin (surrogate for diabetes) increased PsA risk (OR 1.18 per 6.7 mmol/mol increase; 1.02, 1.36) but not psoriasis. Genetic liability to PsA (OR 1.05; 1.003, 1.09) and psoriasis (OR 1.03; 1.001, 1.06) were associated with increased risk of CAD.
conclusionObservational and genetic evidence converge to suggest that BMI and glycaemic control are associated with increased psoriatic disease risk, while psoriatic disease is associated with increased CAD risk. Further research is needed to understand the mechanism of these associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.